Outcomes after a virological failure to first-line second-generation INSTI-based therapy in a real-life setting

Rebecka Papaioannu Borjesson(Vita-Salute San Raffaele University), Vincenzo Spagnuolo(Vita-Salute San Raffaele University), Riccardo Lolatto(Vita-Salute San Raffaele University), Martina Bottanelli(Vita-Salute San Raffaele University), Hamid Hasson(Vita-Salute San Raffaele University), Laura Galli(Vita-Salute San Raffaele University), Arianna Forniti(Azienda Ospedaliera Universitaria Pisana), Nicola Gianotti(Vita-Salute San Raffaele University), Sara Diotallevi(Vita-Salute San Raffaele University), Camilla Muccini(Vita-Salute San Raffaele University), Antonella Castagna(Vita-Salute San Raffaele University), Tommaso Clemente(Vita-Salute San Raffaele University)
Journal of Antimicrobial Chemotherapy
November 21, 2024
10.1093/jac/dkae420
Cited by 2

Related Papers

Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors
|BMJ Open|2024|21
One Year of Long-Acting Cabotegravir and Rilpivirine in People With Human Immunodeficiency Virus and Long Exposure to Antiretroviral Therapy: Data From the SCohoLART Study
|Open Forum Infectious Diseases|2024|20
Persistent ocular mpox infection in an immunocompetent individual
|The Lancet Infectious Diseases|2023|18
Inflammation burden score in multidrug-resistant HIV-1 infection
|Journal of Infection|2023|8
In-depth Analysis of the HIV Reservoir Confirms Effectiveness and Safety of Dolutegravir/Lamivudine in a Phase 4 Randomized Controlled Switch Trial (RUMBA)
|The Journal of Infectious Diseases|2024|8